Health
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus bendamustine plus rituximab (BR), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions. Pirtobrutinib met its primary endpoint demonstrating a reduction in the risk of disease progression or death by 80% (HR=0.20 [95% CI, 0.11-0.37];
About this update from Eli Lilly And Company
[{"type":"text","content":"The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study ","length":141,"tagName":"p","attribs":{}},{"type":"text","content":"These data will be simultaneously published in the Journal of Clinical Oncology and highlighted in a late-breaking oral presentation at the 2025 American Society of Hematology Annual Meeting and Exposition, and were featured as part of the meeting's press program ","length":292,"tagName":"p","attribs":{}},{"type":"text","content":"INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus bendamustine plus rituximab (BR), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions. Pirtobrutinib met its primary endpoint demonstrating a reduction in the risk of disease progression or death by 80% (HR=0.20 [95% CI, 0.11-0.37]; p<0.0001).","length":566,"tagName":"p"},{"type":"image","alt":"Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)","displaySize":"","headline":null,"caption":"Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":219,"url":"https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NS1bi_pPQnL0iU7US5eeOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM4NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee","width":400,"height":219}},"href":"https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"These data will be highlighted in a late-breaking oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida and simultaneously published in the Journal of Clinical Oncology.","length":245,"tagName":"p"},{"type":"text","content":""The results from BRUIN CLL-313 show a significant effect size, among the most pronounced ever observed for a single agent BTK inhibitor in a front-line...